Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Natural killer-like T lymphocytes termed cytokine-induced killer (CIK) cells have been shown to eradicate established tumours in a severe combined immune deficient (SCID) mouse/human lymphoma model. Recently, we demonstrated that CIK cells transfected with cytokine genes possess an improved proliferation rate and a significantly higher cytotoxic activity as compared to non-transfected cells. Here, in a phase I clinical protocol, autologous CIK cells were generated from peripheral blood obtained by leukapheresis in patients with metastatic renal cell carcinoma, colorectal carcinoma and lymphoma. CIK cells were transfected with a plasmid containing the interleukin-2 (IL-2) gene via electroporation. Transfected cells generated IL-2 in the range of 330-1800 pg 10(-6) cells 24 h(-1) with a mean of 836 pg 10(-6) cells 24 h(-1). Ten patients received 1-5 intravenous infusions of IL-2-transfected CIK cells; five infusions with transfected CIK cells were given. In addition, the same patients received five infusions with untransfected CIK cells for control reasons. In three patients, WHO grade 2 fever was observed. Based on polymerase chain reaction of peripheral blood transfected cells could be detected for up to 2 weeks after infusion. There was a significant increase in serum levels of interferon gamma (IFN-gamma), granulocyte-macrophage colony-stimulating factor (GM-CSF) and transforming growth factor beta (TGF-beta) during treatment. Interestingly, there was also an increase in CD3+ lymphocytes in the blood of patients during therapy. In accordance, a partial increase in cytotoxic activity in peripheral blood lymphocytes (PBLs) was documented when patient samples before and after therapy were compared. Concerning clinical outcome, six patients remained in progressive disease, three patients showed no change by treatment, and one patient with lymphoma developed a complete response. In conclusion, we were able to demonstrate that CIK cells transfected with the IL-2 gene can be administered without major side-effects and are promising for future therapeutic trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.6.1823 · Cited by 2,204
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880 · cited 1×
“The goal of this kind of therapy stimulate the immune system to recognize and kill cancer by modifying tumour cells or modifying the host respon Indeed, autologous immunological effector cells have been successfully to treat patients with advanced stage maligna (Rosenberg et al, 1986, 1990).”
BackgroundRosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230904 · Cited by 1,318 · cited 1×
“The goal of this kind of therapy stimulate the immune system to recognize and kill cancer by modifying tumour cells or modifying the host respon Indeed, autologous immunological effector cells have been successfully to treat patients with advanced stage maligna (Rosenberg et al, 1986, 1990).”
BackgroundSchmidt-Wolf, I. G., Negrin, R. S., Kiem, H. P., Blume, K. G., & Weissman, I. L. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.1.139 · Cited by 614 · cited 1×
“In a tumour colony assay these cells were capab generating a log cell kill of 2.5–3.5 (Schmidt-Wolf et al, 1991).”
InfluentialSelf-citationLysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Lotze, M. T., Grimm, E. A., Mazumder, A., Strausser, J. L., & Rosenberg, S. A. (1981) · PubMed · Cited by 523
Lu, P. H., & Negrin, R. S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1687 · Cited by 429
Tumor suppressor activity of the TGF-β pathway in human cancers
Markowitz, S. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/1359-6101(96)00001-9 · Cited by 416
Human IL-7: a novel T cell growth factor.
Welch, P. A., Namen, A. E., Goodwin, R. G., Armitage, R., & Cooper, M. D. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.11.3562 · Cited by 159 · cited 1×
“…first V, d to ll re at from fore ied r for basis h 5- a, auer age of ected asy andom idual med erg, ed. sed , l and LAK (Lotze et al, 1981; Welch et al, 1989) and CIK ce depend on exogenous addition of cytokines like IL-2, IL-7 or 12 for proliferation (Csipai et al, 1996; Zoll et al,…”
BackgroundActivated T cells and cytokine-induced CD3 + CD56 + killer cells
Schmidt‐Wolf, G., Negrin, R. S., & Schmidt‐Wolf, I. G. H. (1997) · Annals of Hematology · doi:10.1007/s002770050257 · Cited by 134
Self-citation
Cited by
Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
Lee, J. H., Lee, J.-H., Lim, Y.-S., Yeon, J. E., Song, T.-J., Yu, S. J., Gwak, G.-Y., Kim, K. M., Kim, Y. J., Lee, J. W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.055 · Cited by 503
Cytokines and Immune Response in the Tumor Microenvironment
Mocellin, S., Wang, E., & Marincola, F. M. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200109000-00002 · Cited by 259
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
“The use of LAK cells is limited to few cancer types due to their difficult amplification and associated adverse effects (166, 167).”
BackgroundLeemhuis, T., Wells, S., Scheffold, C., Edinger, M., & Negrin, R. S. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2004.11.019 · Cited by 210
Metadata
- Authors
- Schmidt-Wolf, I. G. H., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H.-G., Prange, G., Korte, M., Takeya, M., Dorbic, T., Neubauer, A., Wittig, B., & Huhn, D.
- Venue
- British Journal of Cancer
- Published
- 1999-10-29
- Volume
- 81
- Issue
- 6
- Pages
- 1009-1016
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1987052003
- Cited by
- 219
- References
- 15
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6690800
- The paper
- Schmidt-Wolf, I. G. H., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., Heuft, H.-G., Prange, G., Korte, M., Takeya, M., Dorbic, T., Neubauer, A., Wittig, B., & Huhn, D. (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6690800
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.